Urological Research

, Volume 20, Issue 4, pp 313–316 | Cite as

Ras oncogene point mutations in bladder cancer resistant to cisplatin

  • D. P. WoodJr.
  • A. E. Anderson
  • R. Fair
  • R. S. K. Chaganti
Original Articles


Bladder tumors respond to cisplatin-based chemotherapy in 68% of cases, but only 30% will have a durable response. Recent studies have suggested that ras point mutations may produce cisplatin drug resistance in cell lines. To determine the role of ras point mutations in human tumors resistant to cisplatin, we evaluated ten tumors exposed to cisplatin and eight untreated bladder tumors for ras point mutations. Using polymerase chain reaction DNA amplification and allele-specific oligohybridization, we found that only one of the ten treated tumors and none of the untreated tumors harbored a ras point mutation. We conclude that ras point mutations occur infrequently in untreated bladder tumors and do not appear to correlate with cisplatin drug resistance in vivo.

Key words

Ras point mutations Cisplatin-resistant bladder cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andrews PA, Murphy MP, Howell SB (1987) Metallothioneinmediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 19:149Google Scholar
  2. 2.
    Bos JL (1989) ras oncogene in human cancer: a review. Cancer Res 49:4682Google Scholar
  3. 3.
    Fujita J, Strivastava SK, Kraus MH, Rhim JS, Tronick SR, Aaronson SA (1985) Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors. Proc Natl Acad Sci USA 82:3849Google Scholar
  4. 4.
    Ganguly S, Murty VVVS, Samaniego F, Reuter VE, Bosl GJ, Chaganti RSK (1990) Detection of preferential N-ras mutations in human male germ cell tumors by the polymerase chain reaction. Genes, Chromosomes and Cancer 1:228Google Scholar
  5. 5.
    Hamilton TC, Winkler MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols RF (1985) Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and-sensitive human ovarian cancer cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34:2583Google Scholar
  6. 6.
    Isonishi S, Andrews PA, Howell SB, Lazo J (1990) Overexpression of ras oncogene confers resistance to cisplatin (abstract 2156) Proc Am Assoc Cancer Res 31:364Google Scholar
  7. 7.
    Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241:1813Google Scholar
  8. 8.
    Maniatis T, Fritsch EF, Sambrook J (1982) Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NYGoogle Scholar
  9. 9.
    Masuda H, Ozols RF, Lai G-M, Fojo A, Rothenberg M, Hamilton TC (1988) Increased DNA repair as a mechanism of acquired resistance of cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res 48:5713Google Scholar
  10. 10.
    Meyers FJ, Palmer JM, Hannigan JF (1988) Chemotherapy of disseminated transitional cell carcinoma. In: Williams RD (ed) Advances in urologic oncology, vol 1. General perspectives. Macmillan, New York, p 183Google Scholar
  11. 11.
    Morse MJ, Whitmore WF Jr (1986) Neoplasms of the testis. In: Walsh PC, Gittes RF, Perlmutter AD, Stamey TA (eds) Campbell's urology, vol 2. Saunders, New York, pp 1535–1582Google Scholar
  12. 12.
    Nanus DM, Mentle IR, Motzer RJ, Bander NH, Albino AP (1990) Infrequent ras oncogene point mutations in renal cell carcinoma. J Urol 143:175Google Scholar
  13. 13.
    Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487Google Scholar
  14. 14.
    Schmidt CJ, Hamer DH (1986) Cell specificity and an effect of ras on human metallothionein gene expression. Proc Natl Acad Sci USA 83:3346Google Scholar
  15. 15.
    shih C, Weinberg RA (1982) Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29:161Google Scholar
  16. 16.
    Sklar MD (1988) Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res 48:793Google Scholar
  17. 17.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weiselberg L, Rosado K, Smart T, Lin S, Penenberg D, Fair WR, Whitmore WF Jr (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer 64:2448Google Scholar
  18. 18.
    Thrall BD, Meadows GG (1990) Induction of glutathione content in murine melanocytes after transfection with H-ras oncogene (abstract 2156) Proc Am Assoc Cancer Res 31:364Google Scholar
  19. 19.
    Verlaan-de Vries M, Bogaard ME, Van den Elst H, Van Boom JH, Bos JL (1986) A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides. Gene 50:313Google Scholar
  20. 20.
    Visvanathan KV, Pocock RD, Summerhayes IC (1988) Preferential and novel activation of H-ras in human bladder carcinoma. Oncogene Res 3:77Google Scholar
  21. 21.
    Wellner VP, Anderson ME, Puri RN, Jensen GL, Meister A (1984) Radioprotection by glutathione ester transport of glutathione ester into human lympoid cells and fibroblasts. Proc Natl Acad Sci USA 81:4732Google Scholar
  22. 22.
    Yagoda A (1987) Chemotherapy of urothelial tract tumors. Cancer 60:574Google Scholar
  23. 23.
    Zwelling LA, Anderson T, Kohn KW (1979) DNA-protein and DNA interstrand cross-links by cis- and trans-platinum(II) diamine dichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 39:365Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • D. P. WoodJr.
    • 1
    • 2
  • A. E. Anderson
    • 1
  • R. Fair
    • 2
  • R. S. K. Chaganti
    • 1
    • 3
  1. 1.Laboratory of Cancer GeneticsSloan-Kettering InstituteNew YorkUSA
  2. 2.Urology Service, Department of Surgery Memorial HospitalMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Department of Pathology, Memorial HospitalMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations